Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib induction therapy for locally advanced head and neck sarcoma
ChiCTR2000036605Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in head and neck sarcoma, osteosarcoma (OS), chondrosarcoma and 1 more, sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective remission rate of tumor. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
head and neck sarcomaosteosarcoma (OS)chondrosarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2000036605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036605.